Lauren Dembeck, PhD

Researchers determined that few patients with poor risk aRCC were receiving first-line avelumab plus axitinib.

The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months.

The investigators aimed to understand how oncologists decide between IO/IO and IO/TKI treatment options via survey.

Patients with BAP1-mutant ccRCC have very poor prognosis and comprise 10% to 15% of ccRCC cases.

Researchers hypothesized that adverse radiologic and pathologic T3 features are predictive of worse outcomes in small renal masses.

Investigators presented the longest phase 3 follow up reported for a checkpoint inhibitor combination therapy in aRCC.

A total of 651 patients with clear cell aRCC were randomly assigned to receive nivolumab plus cabozantinib or sunitinib.

A retrospective physician-administered chart review evaluated AEs and management strategies used in United States clinical practice among adult patients with aRCC.

No major difference in outcome was observed in a retrospective analysis of patients with mRCC and bone metastasis treated with IO with and without prior radiation.